ONO 1301

• Description :

  ONO 1301 (ONO-AP 500-02), a prostaglandin (PG) I2 mimetic, is an orally active, long-acting prostacyclin agonist with thromboxane-synthase inhibitory activity. ONO 1301 promotes production of hepatocyte growth factor (HGF) from various cell types and ameliorates ischemia-induced left ventricle dysfunction in the mouse, rat and pig[1][2][3].

• Product Name Alternative :

  ONO-AP 500-02

• UNSPSC :

  12352005

• Hazard Statement :

  H302-H312-H332

• Target :

  Prostaglandin Receptor

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Cardiovascular Disease

• Assay Protocol :

  https://www.medchemexpress.com/ono-1301.html

• Purity :

  99.02

• Solubility :

  DMSO : 50 mg/mL (ultrasonic)

• Smiles :

  OC(COC1=C2C(C(CCO/N=C(C3=CN=CC=C3)\C4=CC=CC=C4)=CCC2)=CC=C1)=O

• Molecular Formula :

  C26H24N2O4

• Molecular Weight :

  428.49

• Precautions :

  P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P363-P501

• References & Citations :

  [1]Hirata Y, et al. Beneficial effect of a synthetic prostacyclin agonist, ONO-1301, in rat autoimmune myocarditis model. Eur J Pharmacol. 2013;699 (1-3) :81-87. |[2]Kashiwagi H, et al. The novel prostaglandin I2 mimetic ONO-1301 escapes desensitization in an antiplatelet effect due to its inhibitory action on thromboxane A2 synthesis in mice. J Pharmacol Exp Ther. 2015;353 (2) :269-278. |[3]Kanayama S, et al. ONO-1301 Enhances in vitro Osteoblast Differentiation and in vivo Bone Formation Induced by Bone Morphogenetic Protein. Spine (Phila Pa 1976) . 2018;43 (11) :E616-E624.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C, 3 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [176391-41-6]